

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wolfgang E. BERDEL *et al.*

Appln. No.: 10/569,076

Filed: February 21, 2006

For: Fusion Polypeptides, and Use Thereof
in Antivascular Tumor-Therapy

Art Unit: 1647

Examiner: Marianne P. Allen

Confirmation No.: 7498

Atty. Docket: 20490.003/
P30712US00

Information Disclosure Statement

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to consider the reference listed on the attached Form PTO-1449. A copy of the reference is submitted herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Certification and/or Fee

Because this Information Disclosure Statement is being submitted after issuance of the first action on the merits of the above-captioned application, a fee of \$180.00 is due pursuant to 37 C.F.R. § 1.17(p). Authorization to charge the official fees for this filing is given in the accompanying transmittal letter.

Respectfully submitted,



David R. Marsh (Reg. No. 41,408)
Kristan L. Lansbery (Reg. No. 53,183)

Date: February 26, 2009

ARNOLD & PORTER LLP
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile